Results 101 to 110 of about 704 (128)

Predicting tuberculosis drug efficacy in preclinical and clinical models from <i>in vitro</i> data. [PDF]

iScience
Goh JJN, Patel A, Ngara B, van Wijk RC, Strydom N, Wang Q, Van N, Washington TM, Nuermberger EL, Aldridge BB, Roubert C, Sarathy J, Dartois V, Savic RM.   +13 more
europepmc   +1 more source

Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586. [PDF]

Sci Adv
Thu VTA, Nhu NQ, Anh NTV, Lim SA, Seong HJ, Md Rasheduzzaman J, Kim U, Cho HS, Soedarsono S, Shin JG, Cho YS.   +10 more
europepmc   +1 more source

Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes. [PDF]

Nat Microbiol
Jovanovic A, Bright FK, Sadeghi A, Wicki B, Caño Muñiz SE, Giannini GC, Toprak S, Sauteur L, Rodoni A, Wüst A, Lupien A, Borrell S, Grogono DM, Wheeler NE, Dehio P, Nemeth J, Pargger H, Thomson R, Bell SC, Gagneux S, Bryant JM, Peng T, Diacon AH, Floto RA, Abanto M, Boeck L.   +25 more
europepmc   +1 more source

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. [PDF]

Nat Rev Drug Discov
Dartois V, Dick T.
europepmc   +1 more source

Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. [PDF]

Antimicrob Agents Chemother
Encinas L, Li S-Y, Rullas-Trincado J, Tasneen R, Tyagi S, Soni H, Garcia-Perez A, Lee J, González Del Río R, De Mercado J, Sousa V, Sosič I, Gobec S, Mendoza-Losana A, Converse PJ, Mdluli K, Fotouhi N, Barros-Aguirre D, Nuermberger EL.   +18 more
europepmc   +1 more source

Linezolid pharmacokinetics in multidrug resistant tuberculosis (MDR TB): a systematic review, meta-analysis and Monte Carlo simulation [PDF]

, 2018
Alffenaar, Jan-Willem C, Bolhuis, Mathieu, Bonnett, LJ, Caws, Maxine, Dartois, Veronique, Davies, Geraint, Hodel, eva, Johnson, John L, Millard, james, Pertinez, henry, Sloan, Derek, Tiberi, Simon   +11 more
core  

Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon. [PDF]

Acta Pharm Sin B
Kufa M, Finger V, Kovar O, Soukup O, Torruellas C, Roh J, Korabecny J.   +6 more
europepmc   +1 more source

The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review. [PDF]

Infect Dis Ther
Chen T, Li W, Shen F, Nie W, Wu F.
europepmc   +1 more source

SuFEx-based antitubercular compound irreversibly inhibits Pks13. [PDF]

Nature
Krieger IV, Sukheja P, Yang B, Tang S, Selle D, Woods A, Engelhart C, Kumar P, Harbut MB, Liu D, Tsuda B, Qin B, Bare GAL, Li G, Chi V, Gambacurta J, Hvizdos J, Reagan M, Jones IL, Massoudi LM, Woolhiser LK, Cascioferro A, Kundrick E, Singh P, Reiley W, Ioerger TR, Kandula DR, McCabe JW, Guo T, Alland D, Boshoff HI, Schnappinger D, Robertson GT, Mdluli K, Lee KJ, Dong J, Li S, Schultz PG, Joseph SB, Love MS, Sharpless KB, Petrassi HM, Chatterjee AK, Sacchettini JC, McNamara CW.   +44 more
europepmc   +1 more source